Lenvatinib

Lenvatinib is anticancer drug which is multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.

Indications

locally recurrent or metastatic, progressive, radioactive iodine-refractory Differentiated Thyroid Carcinoma, in combination with everolimus for the treatment of patients with advanced Renal cell carcinoma following one prior anti-angiogenic therapy.

Dosage

Oral; 14-28 mg daily dose modification to be done according to grade of carcinoma.

Contra-Indications

Data not sufficient.

Special Precautions

Paediatric: safety and effectiveness in pediatric patients have not been established. Pregnancy: No human data available. It has teratogenic effect in animal studies. Lactation: advise women to discontinue breastfeeding during treatment. Elderly: No difference in safety and efficacy was found in young and elderly people.

Side Effects

Hypertension, Cardiac Dysfunction, Arterial Thromboembolic Events, Hepatotoxicity , Proteinuria , Diarrhea, Renal Failure and Impairment, diarrhea, fatigue, Gastrointestinal Perforation and Fistula Formation, QT Interval Prolongation, Hypocalcemia, Reversible Posterior Leukoencephalopathy Syndrome, Hemorrhagic Events, Impairment of Thyroid Stimulating Hormone Suppression/Thyroid Dysfunction, Wound Healing Complications.

Drug Interactions

Data not sufficient.